NFKB1 and steatosis: MCC950 prevented the rise in AST and ALT in foz/foz mice and in WT mice and resulted in decreased NFκB activation, leading to less liver inflammation and overall improvement in the NAFLD activity score (NAS) score, without any effect on steatosis as observed on histology [135].